Delcath Systems Inc (DCTH)vsEli Lilly and Company (LLY)
DCTH
Delcath Systems Inc
$13.01
-3.77%
HEALTHCARE · Cap: $446.71M
LLY
Eli Lilly and Company
$1,188.01
-2.33%
HEALTHCARE · Cap: $1.08T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 79785% more annual revenue ($72.25B vs $90.44M). LLY leads profitability with a 35.0% profit margin vs 0.6%. LLY appears more attractively valued with a PEG of 1.57. LLY earns a higher WallStSmart Score of 76/100 (B+).
DCTH
Hold35
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 26.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.5% — below average capital efficiency
0.6% margin — thin
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 1294.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 43.9x leaves little room for execution misses.
Key Dynamics to Monitor
DCTH carries more volatility with a beta of 0.52 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?